Skip header and navigation

Refine By

   MORE

7 records – page 1 of 1.

Certain biophysical properties of Ukrain.

https://arctichealth.org/en/permalink/ahliterature22890
Source
Drugs Exp Clin Res. 1996;22(3-5):185-7
Publication Type
Article
Date
1996
Author
Y M Susak
M V Kurik
O V Kravchenko
S V Zemskov
Author Affiliation
Department of General Surgery, Ukrainian State Medical University, Kiev Institute of Physics, Ukraine.
Source
Drugs Exp Clin Res. 1996;22(3-5):185-7
Date
1996
Language
English
Publication Type
Article
Keywords
Alkaloids - blood - chemistry
Antineoplastic Agents - blood - chemistry
Chemistry, Physical
Colorectal Neoplasms - blood - drug therapy
Drug Stability
Humans
Photochemistry
Spectrophotometry, Ultraviolet
Spectrum Analysis - methods
Abstract
Ukrain was found to be relatively resistant in vitro to mean intensity radiation over the whole UV range. Of the seven peaks in the absorption spectrum of Ukraine those at 210 and 230 nm are conspicuous in the spectrum of the plasma of colorectal patients injected the previous day with this drug.
PubMed ID
8899327 View in PubMed
Less detail

[Clinical significance of K-RAS and cytokeratine 20 markers in diagnosis of lymphogenic metastasis of pancreatic cancer]

https://arctichealth.org/en/permalink/ahliterature16492
Source
Klin Khir. 2005 Aug;(8):32-5
Publication Type
Article
Date
Aug-2005
Author
S V Zemskov
Source
Klin Khir. 2005 Aug;(8):32-5
Date
Aug-2005
Language
Ukrainian
Publication Type
Article
Keywords
Adenocarcinoma - diagnosis - genetics - pathology - surgery
Disease-Free Survival
English Abstract
Genes, ras - genetics
Humans
Keratin - genetics
Lymphatic Metastasis
Mutation
Pancreatic Neoplasms - diagnosis - genetics - pathology - surgery
Pancreaticoduodenectomy
Polymorphism, Restriction Fragment Length
Reverse Transcriptase Polymerase Chain Reaction
Tumor Markers, Biological - genetics
Abstract
Aim of the work is to estimate the role of the metastases molecular signs (MMS) in paraaortal lymphatic nodes, revealed using combined molecular-biological method with application of K-RAS markers and cytokeratine 20 (CK20) for the survival prognostication in the pancreatic head cancer patients after performing pancreatoduodenal resection. Actuarial index of general survival of the patients with MMS in paraaortal lymphatic nodes was trustworthy lower than in patients without such a signs. The two-year survival index in patients without MMS was 60%, the survival mediana--32 mo. Any of the patients with MMS did not survive two years, the survival mediana was 13 mo.
PubMed ID
16445057 View in PubMed
Less detail

[Transcutaneous electric stimulation of the liver and bile ducts during active enterosorption in combined surgical treatment of obstructive jaundice of nontumorous etiology]

https://arctichealth.org/en/permalink/ahliterature56709
Source
Klin Khir. 1998;(12):8-10
Publication Type
Article
Date
1998
Author
O I Pryluts'kyi
L F Horovyi
S V Zemskov
Source
Klin Khir. 1998;(12):8-10
Date
1998
Language
Ukrainian
Publication Type
Article
Keywords
Adult
Aged
Bile Duct Diseases - therapy
Cholecystitis - therapy
Cholestasis - surgery - therapy
Combined Modality Therapy
Comparative Study
English Abstract
Enterosorption
Female
Gallstones - therapy
Hepatitis - therapy
Humans
Liver Diseases - therapy
Liver Failure - therapy
Male
Middle Aged
Transcutaneous Electric Nerve Stimulation
Abstract
The influence of transcutaneous electrostimulation of liver and biliferous ducts while conduction of desintoxication using chitinous enterosorbent "Mikoton" on the result of treatment of hepatargy in patients with obstructive jaundice of nontumoral genesis in the early postoperative period was studied.
PubMed ID
10077935 View in PubMed
Less detail

Ukrain (NSC-631570) in the treatment of pancreas cancer.

https://arctichealth.org/en/permalink/ahliterature19823
Source
Drugs Exp Clin Res. 2000;26(5-6):179-90
Publication Type
Article
Date
2000
Author
V S Zemskov
O L Procopchuk
Y M Susak
S V Zemskov
Y Y Hodysh
M V Zemskova
Author Affiliation
Kyiv Centre for Hepato-Pancreato-Biliary Surgery, Kiev, Ukraine.
Source
Drugs Exp Clin Res. 2000;26(5-6):179-90
Date
2000
Language
English
Publication Type
Article
Keywords
Adult
Aged
Alkaloids - adverse effects - therapeutic use
Antineoplastic Agents, Phytogenic - adverse effects - therapeutic use
Body Weight - drug effects
Female
Humans
Karnofsky Performance Status
Male
Middle Aged
Pain Measurement
Pancreatic Neoplasms - drug therapy
Pilot Projects
Survival Analysis
Abstract
The aim of this study was to investigate the effects of Ukrain in the treatment of pancreatic cancer. Most patients with advanced pancreas cancer experience pain and have to limit their daily activities because of tumor-related symptoms. Currently, there is no satisfactory treatment for pancreas cancer. The 12-month survival rate is approximately 18% for patients treated with gemcitabine and only around 2% for those treated with 5-fluorouracil. Between January 1, 1996 and December 31, 1999 42 patients with advanced symptomatic pancreas cancer were randomly assigned to receive either vitamin C (5.4 g every second day, repeated 10 times) and Ukrain (10 mg every second day, repeated 10 times) (21 patients), or vitamin C (5.4 g every second day x 10) and normal saline (10 ml) (control group, 21 patients). The primary measure of efficacy was overall survival. Other evaluation criteria included change in body weight, pain intensity (measured by analgesic consumption) and Kamofsky performance status. The one-year survival was 81% in the Ukrain group compared with 14% in the control group. The 2-year survival was 43% in the Ukrain group compared with 5% in the control group. In a recent study of 126 patients treated with gemcitabine or 5-fluorouracil, none of the patients survived beyond 19 months. The longest survival in the Ukrain group was 54 months after the start of therapy (from March 1996 to date). The last follow-up of other patients was on September 6, 2000. Median survival was 17.17 months for Ukrain-treated patients and 6.97 months for the control group and mean survival was 21.86 and 8.92 months for the Ukrain and control groups, respectively (p = 0.001). Ukrain treatment was well tolerated. We conclude that Ukrain prolongs survival of pancreas cancer patients. To determine whether and to what extent this drug can be used as standard therapy in pancreas cancer, a phase III study should be carried out.
PubMed ID
11345025 View in PubMed
Less detail

Ukrain treatment in a patient with breast carcinoma. Case report.

https://arctichealth.org/en/permalink/ahliterature19815
Source
Drugs Exp Clin Res. 2000;26(5-6):253-4
Publication Type
Article
Date
2000
Author
S V Zemskov
O L Prokopchuk
Y M Susak
Author Affiliation
Department of General Surgery, Ukrainian State Medical University, Kiev, Ukraine.
Source
Drugs Exp Clin Res. 2000;26(5-6):253-4
Date
2000
Language
English
Publication Type
Article
Keywords
Alkaloids - therapeutic use
Antineoplastic Agents, Phytogenic - therapeutic use
Breast Neoplasms - drug therapy - pathology - surgery
Carcinoma - drug therapy - pathology - surgery
Female
Humans
Middle Aged
Abstract
A 50-year-old female patient with breast cancer (stage IV) was treated with Ukrain because of the impossibility of radiotherapy and chemotherapy. The first course led to a subjective improvement in her general condition, objective changes such as the appearance of border between the tumor and healthy tissues and a decrease in tumor size. Ukrain facilitated the surgeon in performing an operation to remove the primary tumor as well as the metastatic lymph nodes. After the second and third courses of Ukrain, the patient demonstrated clinical remission.
PubMed ID
11345033 View in PubMed
Less detail

Ukrain treatment in a patient with metastatic renal cell carcinoma extending to the vena cava inferior. Case report.

https://arctichealth.org/en/permalink/ahliterature19813
Source
Drugs Exp Clin Res. 2000;26(5-6):257-9
Publication Type
Article
Date
2000
Author
O L Prokopchuk
S V Zemskov
Y M Susak
Author Affiliation
Kiev Centre of Hepato-Pancreato-Biliary Surgery, Kiev, Ukraine.
Source
Drugs Exp Clin Res. 2000;26(5-6):257-9
Date
2000
Language
English
Publication Type
Article
Keywords
Alkaloids - adverse effects - therapeutic use
Antineoplastic Agents, Phytogenic - adverse effects - therapeutic use
Carcinoma, Renal Cell - drug therapy - pathology - surgery
Combined Modality Therapy
Humans
Immunity, Cellular - drug effects
Kidney Neoplasms - drug therapy - pathology - surgery
Male
Middle Aged
Quality of Life
Vascular Neoplasms - drug therapy - secondary - surgery
Vena Cava, Inferior - pathology
Abstract
A 52-year-old man with renal cell carcinoma was treated with surgery and chemotherapy (vinblastine). Ukrain was administered after tumor progression to the vena cava inferior and appearance of liver metastasis. The drug induced a complete remission, which has lasted 32 months since the first therapy course.
PubMed ID
11345035 View in PubMed
Less detail

Ukrain treatment of a patient with retroperitoneal synovial sarcoma. Case report.

https://arctichealth.org/en/permalink/ahliterature19814
Source
Drugs Exp Clin Res. 2000;26(5-6):255-6
Publication Type
Article
Date
2000
Author
O L Prokopchuk
S V Zemskov
Y M Susak
Author Affiliation
Department of General Surgery, Ukrainian State Medical University, Prosp. 40-richya Zhovtnya 59-A, Kyiv, Ukraine.
Source
Drugs Exp Clin Res. 2000;26(5-6):255-6
Date
2000
Language
English
Publication Type
Article
Keywords
Adult
Alkaloids - adverse effects - therapeutic use
Antineoplastic Agents, Phytogenic - adverse effects - therapeutic use
Female
Humans
Immunity, Cellular - drug effects
Retroperitoneal Neoplasms - drug therapy - pathology - surgery
Sarcoma, Synovial - drug therapy - pathology - surgery
Abstract
A 23-year-old woman, diagnosed with a synovial sarcoma of the peritoneum, underwent an operation for tumor extraction. In the postoperative period, Ukrain was injected i.v. at a dose of 10 mg on alternate days, for a total of 10 injections. After a 2-month break, this schedule was repeated. Ukrain treatment was well tolerated by the patient and there were no complications in the postoperative period. The following changes in immunohematological parameters were observed: increased total leucocytes, T lymphocytes and T helpers. Nearly 4 years after Ukrain therapy, the patient is in complete remission.
PubMed ID
11345034 View in PubMed
Less detail

7 records – page 1 of 1.